The Complainant is a German family-owned pharmaceutical group of companies with roots going back to 1885, when it was founded by Albert Boehringer (1861-1939) in Ingelheim am Rhein. Ever since, it has become a global research-driven pharmaceutical enterprise and it has today roughly 53,500 employees. The Complainant's two business areas are: human pharmaceuticals and animal health. In 2023, the Complainant achieved net sales of 25.6 billion Euros.<\/p>\n
The disputed domain name <boehringer-ingelheimfrance.com> was registered on 27 August 2024 and, at the moment of the issuance of this decision, resolves to an e-commerce website in French selling pharmaceuticals and containing the Complainant's logo in its header.<\/p>\n
The facts asserted by the Complainant are not contested by the Respondent.<\/p>", "other_legal_proceedings": "
The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain name.<\/p>", "no_response_filed": "
The Complainant contends that all requirements of the Policy have been met and that the disputed domain name should be transferred to it.<\/p>\n
No administratively compliant Response has been filed.<\/p>", "rights": "
The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>", "no_rights_or_legitimate_interests": "
The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>", "bad_faith": "
The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>", "procedural_factors": "
Upon commencement of the administrative proceedings, the Respondent replied to the e-mail notification of the CAC with the message: “What is this?”. The CAC has provided the Respondent with detailed information about the procedure. The Respondent has neither contacted the CAC again, nor has submitted a Response.<\/p>\n
The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>", "decision": "Accepted", "panelists": [ "Ivett Paulovics" ], "date_of_panel_decision": "2024-09-23 00:00:00", "informal_english_translation": "
The Complainant, conducting business under the company \/ trade name Boehringer Ingelheim Pharma GmbH & Co.KG, owns numerous trademarks including the wording “BOEHRINGER INGELHEIM” registered in several countries, such as:<\/p>\n
Furthermore, the Complainant owns multiple domain names consisting in the wording “BOEHRINGER INGELHEIM”, such as <boehringer-ingelheim.com> registered since 1 September 1995 and used in relation to its main website.<\/p>\n
The above-mentioned rights of the Complainant are hereinafter referred to as the BOEHRINGER INGELHEIM Trademark.<\/p>", "decision_domains": { "boehringer-ingelheimfrance.com": "TRANSFERRED" }, "panelist": null, "panellists_text": null }